Rapid advances in the understanding of solid tumours has lead to exponential growth in the developement of molecularly-targeted therapies. Patients with tumours harbouring specific mutations may be candidates for specific therapies. Additionally, molecular testing can aid in prognostic stratification or identification of treatment-resistant tumours. Due to these advances, molecular testing has been incorporated into international guidelines.
IDYLLA: Advances in Single-Gene Testing for precision oncology